Analyst Price Targets — CATX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 18, 2026 8:21 pm | — | BMO Capital | $11.00 | $3.21 | TheFly | Perspective Therapeutics initiated with an Outperform at BMO Capital |
| March 17, 2026 12:35 pm | Greg Renza | Truist Financial | $12.00 | $5.09 | StreetInsider | Truist Reiterates Buy Rating on Perspective Therapeutics Inc (CATX) |
| February 19, 2026 10:11 am | Biren Amin | Piper Sandler | $16.00 | $5.03 | TheFly | Perspective Therapeutics initiated with an Overweight at Piper Sandler |
| January 30, 2026 11:08 am | — | H.C. Wainwright | $12.00 | $4.26 | TheFly | Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright |
| November 21, 2025 12:26 am | David Lai | UBS | $7.00 | $2.12 | TheFly | Perspective Therapeutics price target lowered to $7 from $18 at UBS |
| October 10, 2025 10:59 am | Jeet Mukherjee | BTIG | $14.00 | $4.20 | TheFly | Perspective Therapeutics initiated with a Buy at BTIG |
| October 24, 2024 3:50 am | David Dai | UBS | $20.00 | $11.69 | StreetInsider | UBS Starts Perspective Therapeutics Inc (CATX) at Buy |
| October 14, 2024 6:07 am | Jeff Jones | Oppenheimer | $22.00 | $12.66 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX) |
| September 25, 2024 6:10 am | Nicole Germino | Truist Financial | $21.00 | $12.28 | StreetInsider | Truist Securities Starts Perspective Therapeutics Inc (CATX) at Buy |
| July 25, 2024 6:11 am | Alec Stranahan | Bank of America Securities | $24.00 | $12.82 | TheFly | Perspective Therapeutics initiated with a Buy at BofA |
Latest News for CATX
Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-term catalysts across its radiopharmaceutical pipeline. The company's bamzireotide navoxetan for SSTR2-expressing NETs shows sustained efficacy and safety, with pivotal Phase 3 initiation targeted for late 2026. Upcoming data readouts for both NET and MC1R-positive melanoma programs, including ESMO 2026 and OPDIVO…
Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 391.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 450,097 shares of the company's stock after buying an additional 358,540 shares during the quarter. Dimensional Fund Advisors
Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 88.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,049,999 shares of the company's stock after purchasing an additional 2,839,266 shares during the quarter.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CATX.
U.S. House Trading
No House trades found for CATX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.